Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
David is a Partner and current Chief Executive Officer and co-founder of Longwood portfolio Company Axial Biotherapeutics. David also serves on the Board of Longwood portfolio companies Millendo and Bicycle Therapeutics . David is an accomplished business development and strategy executive with extensive leadership experience and a track record of building companies. Prior to joining Longwood, David has held various leadership roles at biopharmaceutical companies including AbbVie (NASDAQ: ABBV) and GSK (NYSE: GSK). At AbbVie, David served as Vice President & Global Head of Ventures and Early Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, David served as Vice President Global New Deal Strategy and Development at GlaxoSmithKline, and Senior Manager at Accenture’s Strategic Services Consulting Group.
David holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Alcyone Life Sciences, a privately held CNS company which he co-founded. He is also a strategic advisor to DNATrix, a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer.